Medical Condition

interstitial lung disease

Total Trials

9

Recruiting Now

9

Trial Phases

Phase 2, Phase 1, Phase 2

Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.

Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.

Frequently Asked Questions — interstitial lung disease Clinical Trials

How many clinical trials are currently recruiting for interstitial lung disease?

ClinicalMetric currently tracks 9 actively recruiting clinical trials for interstitial lung disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for interstitial lung disease?

interstitial lung disease research spans Phase 1 (1 trial), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a interstitial lung disease clinical trial?

Eligibility criteria for interstitial lung disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Mayo Clinic 1 trial

Peter Caravan 1 trial

University of Massachusetts, Worcester 1 trial

David Palma 1 trial

McGill University Health Centre/Research Institute of the McGill University Health Centre 1 trial

Recruiting Clinical Trials

NCT03478826

Recruiting

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Enrollment

500 pts

Location

United States, Austr...

Sponsor

University of Massachusetts, W...

View Trial →

NCT05986318 Phase 2

Recruiting

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

ILD-SARDs Registry and Biorepository

McGill University Health Centr...

View Trial →

NCT06574581 Phase 1, Phase 2

Recruiting

ADSCs Therapy in Patients With CTD-ILD

China Medical University Hospi...

View Trial →

NCT07283081

Recruiting

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

University Hospital, Bordeaux

Amsterdam UMC, location VUmc

View Trial →

NCT06038630 Phase 2

Recruiting

129Xe MRI Cardiopulmonary

Related Conditions

pulmonary fibrosis (2) connective tissue diseases (2) progressive pulmonary fibrosis (1) lung cancer (1) systemic autoimmune disease (1) rheumatic diseases (1) rheumatic arthritis (1) systemic sclerosis (1) autoimmune myositis (1) systemic lupus erythematosus (1) usual interstitial pneumonia (1) nonspecific interstitial pneumonia (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology